Publications by authors named "Pantelia Roussou"

Article Synopsis
  • Thrombocytopenia is a common issue in myelofibrosis (MF), and previous trials excluded patients with low platelet counts from receiving ruxolitinib, a treatment for MF.
  • The EXPAND study aimed to determine a safe starting dose of ruxolitinib for patients with low platelet counts (50 to <100 × 10/L) and evaluate its long-term safety and efficacy.
  • The study found that a starting dose of 10 mg twice daily was well-tolerated, with significant clinical benefits for patients, including a notable reduction in spleen size, despite a higher incidence of thrombocytopenia and anemia in the participants.
View Article and Find Full Text PDF

Introduction: The phosphatidylinositol 3-kinase (PI3K) pathway promotes tumor growth and treatment resistance in non-small cell lung cancer (NSCLC). The aim of the open-label, two-stage, Phase II study BASALT-1 (NCT01820325) was to investigate the pan-PI3K inhibitor buparlisib (BKM120) in patients with PI3K pathway-activated, relapsed NSCLC.

Methods: After prescreening for PI3K pathway activation, patients with PI3K pathway-activated, metastatic, squamous or nonsquamous NSCLC, who had relapsed after prior systemic antineoplastic therapy, were enrolled.

View Article and Find Full Text PDF